{"entity":{"id":"ibi3009","kind":"drug","name":"IBI3009","aka":[],"tldr":"IBI3009 is an experimental antibody-drug conjugate for small cell lung cancer, aimed at the protein DLL3. Innovent Biologics licensed it to Roche in January 2025, and it is in a first phase 1 trial.","summary":"IBI3009 is an antibody-drug conjugate that targets DLL3 and carries a payload from Innovent Biologics' topoisomerase 1 inhibitor platform; the registry describes it as a monoclonal antibody-camptothecin derivative conjugate. Innovent announced a collaboration and exclusive licence with Roche on 2 January 2025, by which time IBI3009 had approval to start trials in Australia, China and the United States and the first patient had been dosed in December 2024. The phase 1 trial (NCT06613009), sponsored by Innovent, is enrolling people with unresectable, metastatic or extensive-stage small cell lung cancer. No results are recorded here.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Innovent and Roche licence announcement, January 2025 (Drug Discovery Online copy)","url":"https://www.drugdiscoveryonline.com/doc/innovent-enters-into-exclusive-global-license-roche-for-novel-dll-antibody-drug-conjugate-0001"},{"label":"ClinicalTrials.gov: IBI3009 phase 1 (NCT06613009)","url":"https://clinicaltrials.gov/study/NCT06613009"}],"tags":["pipeline","deal-asset"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":["dll3"],"drugs":[],"companies":["innovent","roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06613009"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit (ClinicalTrials.gov v2 + company press releases)","editedOn":"2026-11-03"},"modality":"Antibody-drug conjugate (DLL3, topoisomerase I inhibitor payload)","mechanism":"An antibody that recognises DLL3, a protein found on small cell lung cancer and other neuroendocrine tumours but rarely on normal tissue, carries a camptothecin-type topoisomerase I inhibitor into the cancer cell.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ibi3009/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"trial":[{"id":"nct06613009","kind":"trial","name":"Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct06613009/"}]}}